Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin

Abstract : Neurotoxicity remains the most common adverse effect of oxaliplatin, limiting its clinical use. In the present study, we developed a mouse model of chronic oxaliplatin-induced neuropathy, which mimics both sensory and motor deficits observed in patients, in a clinically relevant time course. Repeated oxaliplatin administration in mice induced both cephalic and extracephalic long lasting mechanical and cold hypersensitivity after the first injection as well as delayed sensorimotor deficits and a depression-like phenotype. Using this model, we report that riluzole prevents both sensory and motor deficits induced by oxaliplatin as well as the depression-like phenotype induced by cumulative chemotherapeutic drug doses. All the beneficial effects are due to riluzole action on the TREK-1 potassium channel, which plays a central role in its therapeutic action. Riluzole has no negative effect on oxaliplatin antiproliferative capacity in human colorectal cancer cells and on its anticancer effect in a mouse model of colorectal cancer. Moreover, riluzole decreases human colorectal cancer cell line viability in vitro and inhibits polyp development in vivo. The present data in mice may support the need to clinically test riluzole in oxaliplatin-treated cancer patients and state for the important role of the TREK-1 channel in pain perception.
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-02065469
Contributor : Laurence Chauvet <>
Submitted on : Tuesday, March 12, 2019 - 4:50:27 PM
Last modification on : Wednesday, March 13, 2019 - 1:20:22 AM

Identifiers

Collections

Citation

Laura Poupon, Sylvain Lamoine, Vanessa Pereira, David Barriere, Stéphane Lolignier, et al.. Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology, Elsevier, 2018, 140, pp.43-61. ⟨10.1016/j.neuropharm.2018.07.026⟩. ⟨hal-02065469⟩

Share

Metrics

Record views

24